Karen Conrad
Scientific Associate Director, Protein Science, Structural Biology Takeda
Karen S. Conrad is Scientific Associate Director of Protein Chemistry in the Global Structural Biology group at Takeda, where she leads a team responsible for protein production for stakeholders across the organization. She is a protein chemist specializing in membrane protein research, with more than a decade of industrial laboratory experience in small-molecule drug discovery. Karen previously served as Principal Scientist in Physical Biochemistry at Biogen, leading multidisciplinary projects spanning construct design, protein purification, and structural characterization. Earlier in her career, she was a Senior Scientist at Pfizer, contributing to soluble and membrane protein target production and characterization. She completed postdoctoral research at Cornell University in Brian Crane’s lab, focusing on light-activated circadian clock proteins. Karen earned a Ph.D. in Inorganic Chemistry from the University of Wisconsin–Madison in Thomas Brunold’s lab, where her thesis explored the transport and utilization of B12, and holds a B.A. in Chemistry from Claremont McKenna College. Her expertise spans molecular biology, biophysics, structural biology, spectroscopy, and computational analysis.
Seminars
- Assessing the limitations of structure prediction methods such as AlphaFold and exploring how moving beyond static models to dynamic systems can improve protein design outcomes
- Examining how cryo-EM data and co-folding models can be combined to enhance prediction of multi-component interactions in complex biologics
- Understanding what drives the gap between structural accuracy and functional performance, and how to better translate in silico designs into biological activity
- Surveying the protein engineering objectives that enable structural studies of membrane proteins and GPCRs, including the use of soluble analogues and stabilized receptor constructs
- Prioritizing design strategies that deliver structural biology value by improving construct tractability, conformational control, and downstream drug discovery impact